Antimetabolites, Antineoplastic

"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antimetabolites that are useful in cancer chemotherapy.

Descriptor ID	D000964
MeSH Number(s)	D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
Concept/Terms	Antimetabolites, Antineoplastic Antimetabolites, Antineoplastic Antineoplastic Antimetabolites

Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Antimetabolites, Antineoplastic [D27.505.519.186.144]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antimetabolites, Antineoplastic [D27.505.954.248.144]
Toxic Actions [D27.888]
Noxae [D27.888.569]
Antimetabolites [D27.888.569.042]
Antimetabolites, Antineoplastic [D27.888.569.042.030]

Below are MeSH descriptors whose meaning is related to "Antimetabolites, Antineoplastic".

Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.

Bar chart showing 22 publications over 14 distinct years, with a maximum of 2 publications in 2004 and 2007 and 2008 and 2009 and 2011 and 2013 and 2015 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1999	0	1	1
2002	1	0	1
2003	0	1	1
2004	0	2	2
2007	0	2	2
2008	1	1	2
2009	1	1	2
2011	0	2	2
2013	1	1	2
2015	1	1	2
2020	0	2	2
2024	0	1	1
2025	1	0	1

Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.

Muralidharan J, Eswaran M, Bae S, Singh S, Mir H. Elevated CCL20 and IL-10 enhance 5-fluorouracil tolerance in colon cancer. Biomed Pharmacother. 2025 Aug; 189:118258.

View in: PubMed
Umar S, Samokhvalov A. Encapsulation of Gemcitabine on Porphyrin Aluminum Metal-Organic Framework by Mechano-Chemistry, Delayed Drug Release and Cytotoxicity to Pancreatic Cancer PANC-1 Cells. Molecules. 2024 Jul 04; 29(13).

View in: PubMed
Hatami E, Nagesh PKB, Jaggi M, Chauhan SC, Yallapu MM. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. Eur J Pharmacol. 2020 Dec 05; 888:173486.

View in: PubMed
Erfani M, Hosseini SV, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M, Taghavi A, Carethers JM, Koi M, Brim H, Mokarram P, Ashktorab H. Altered ARID1A expression in colorectal cancer. BMC Cancer. 2020 Apr 25; 20(1):350.

View in: PubMed
Sane S, Abdullah A, Nelson ME, Wang H, Chauhan SC, Newton SS, Rezvani K. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. Cell Stress Chaperones. 2016 Mar; 21(2):313-26.

View in: PubMed
Devaney JM, Wang S, Furbert-Harris P, Apprey V, Ittmann M, Wang BD, Olender J, Lee NH, Kwabi-Addo B. Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics. 2015; 10(4):319-28.

View in: PubMed
Devaney JM, Wang S, Funda S, Long J, Taghipour DJ, Tbaishat R, Furbert-Harris P, Ittmann M, Kwabi-Addo B. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):292-300.

View in: PubMed
Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther. 2013 Jun; 14(6):492-501.

View in: PubMed
Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar; 11(3):680-9.

View in: PubMed
Chougule MB, Patel A, Sachdeva P, Jackson T, Singh M. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One. 2011; 6(11):e27394.

View in: PubMed

People

Explore

Similar Concepts

Top Journals